ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES

Vaccine Formulation Institute (Ch) Ltd, Plan-Les-Ouates

Investigators

Abstract

The project will advance the development of a new vaccine adjuvant which addresses the need for more Th1-inducing and affordable adjuvants openly available for vaccine development. An innovative, cost-effective saponin fraction will be formulated within a liposome carrier and formulated with a pan-sarbecovirus vaccine in order to accelerate the development of this new adjuvant. This adjuvant will be made ultimately available to the entire vaccine community. This project encompasses the optimization of the liposome carrier's composition, as well as a comprehensive evaluation of the adjuvant's immune profile. The protective efficacy of the adjuvanted formulation will be evaluated in advanced preclinical studies comprising immunogenicity and safety evaluations. The project also includes the Good Manufacturing Practice (GMP) preparation of the adjuvant, pharmacology and toxicity studies to facilitate its progression towards use in phase 1 clinical studies. This collaborative effort will contribute to accelerate the development of vaccine of Global Health impact.